pcDNA3-sACE2v2.4(732)-IgG1 Citations (4)

Originally described in: Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2.
Chan KK, Dorosky D, Sharma P, Abbasi SA, Dye JM, Kranz DM, Herbert AS, Procko E Science. 2020 Sep 4;369(6508):1261-1265. doi: 10.1126/science.abc0870. Epub 2020 Aug 4. PubMed Journal

---

Articles Citing pcDNA3-sACE2v2.4(732)-IgG1

Articles
Computationally Designed ACE2 Decoy Receptor Binds SARS-CoV-2 Spike (S) Protein with Tight Nanomolar Affinity. Havranek B, Chan KK, Wu A, Procko E, Islam SM. J Chem Inf Model. 2021 Sep 27;61(9):4656-4669. doi: 10.1021/acs.jcim.1c00783. Epub 2021 Aug 24. PubMed
Functional differences among the spike glycoproteins of multiple emerging severe acute respiratory syndrome coronavirus 2 variants of concern. Wang Q, Nair MS, Anang S, Zhang S, Nguyen H, Huang Y, Liu L, Ho DD, Sodroski JG. iScience. 2021 Nov 19;24(11):103393. doi: 10.1016/j.isci.2021.103393. Epub 2021 Nov 1. PubMed
An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2. Zhang L, Narayanan KK, Cooper L, Chan KK, Devlin CA, Aguhob A, Shirley K, Rong L, Rehman J, Malik AB, Procko E. bioRxiv. 2022 Mar 28. doi: 10.1101/2022.03.28.486075. PubMed
Modulation of the pharmacokinetics of soluble ACE2 decoy receptors through glycosylation. Skeeters S, Bagale K, Stepanyuk G, Thieker D, Aguhob A, Chan KK, Dutzar B, Shalygin S, Shajahan A, Yang X, DaRosa PA, Frazier E, Sauer MM, Bogatzki L, Byrnes-Blake KA, Song Y, Azadi P, Tarcha E, Zhang L, Procko E. Mol Ther Methods Clin Dev. 2024 Jul 19;32(3):101301. doi: 10.1016/j.omtm.2024.101301. eCollection 2024 Sep 12. PubMed

If you have published an article using this material, please email us at to have your article added to this page.